Sight Sciences, Inc. Stock Price, News & Analysis

Sight Sciences (NASDAQ:SGHT) announced that its TearCare System has been included in the prestigious TFOS DEWS III report published in the American Journal of Ophthalmology. This recognition represents significant validation for TearCare's clinical efficacy in treating dry eye disease (DED) and meibomian gland disease (MGD).

The report highlights multiple clinical studies supporting TearCare's effectiveness, including the SAHARA trial, which demonstrated clinical superiority over Restasis in improving Tear Breakup Time and gland function, and the OLYMPIA trial, which showed significant improvement in DED symptoms, particularly in severe cases compared to LipiFlow.

Sight Sciences (Nasdaq: SGHT), an eyecare technology company, announced its participation in the Morgan Stanley Global Healthcare Conference in New York. The company's management will deliver a presentation on Wednesday, September 10, 2025, at 10:50 am PT / 1:50 pm ET.

Investors and interested parties can access both the live and archived versions of the fireside chat through the "Investors" section on the company's website at investors.sightsciences.com.

Sight Sciences (NASDAQ: SGHT) reported Q2 2025 financial results, with total revenue of $19.6 million, declining 8% year-over-year. The company's Surgical Glaucoma segment revenue decreased 5% to $19.2 million, primarily due to Medicare coverage restrictions on multiple MIGS procedures.

Despite challenges, the company achieved positive developments including an all-time high of 1,174 Surgical Glaucoma ordering accounts, up 4% year-over-year. Operating expenses decreased 9% to $28.3 million. The company reported a net loss of $11.9 million, or $0.23 per share.

Sight Sciences raised its full-year 2025 revenue guidance to $72.0-$76.0 million while maintaining adjusted operating expenses guidance of $101.0-$105.0 million. The company ended Q2 with $101.5 million in cash and cash equivalents.

Sight Sciences (NASDAQ: SGHT) has announced positive results from a cost-utility analysis comparing its TearCare® System to cyclosporine 0.05% (CsA) for treating meibomian gland disease-associated dry eye disease. The study, published in Expert Review of Pharmacoeconomics and Outcomes Research, demonstrated significant advantages for TearCare.

The analysis revealed that TearCare delivered annual cost savings of $903 per patient ($4,916 vs. $5,819 for CsA) and achieved higher quality-adjusted life years (0.76 QALYs vs. 0.74 QALYs). The study, conducted over a one-year horizon from a US healthcare payer perspective, showed TearCare's superior cost-effectiveness even when adjusting various assumptions in scenario analyses.

Dr. Nathan Lighthizer, lead investigator and Professor at NSU Oklahoma College of Optometry, emphasized these findings align with clinical observations, highlighting TearCare as an economically sustainable treatment option.

Sight Sciences (Nasdaq: SGHT) announced the publication of 24-month results from Stage 3 of the SAHARA randomized controlled trial for its TearCare® System in treating dry eye disease. The study demonstrated significant durability, with 66% of participants requiring no additional treatment beyond the initial two treatments at baseline and Month 5.

The trial showed statistically significant improvements in all measured parameters including tear breakup time, meibomian gland secretion, and patient symptom scores. Key metrics remained improved through the 24-month period, with tear breakup time improving from 4.41 seconds at baseline to 6.29-7.13 seconds, and meibomian gland secretion scores increasing from 7.26 to 18.95.

Sight Sciences (Nasdaq: SGHT), an eyecare technology company, will release its Q2 2025 financial results on August 7, 2025, after market close. The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results.

Investors can access the live webcast and replay of the event through the company's website at www.sightsciences.com in the Investors section under News & Events. The webcast replay will be available for at least 90 days following the event.

Sight Sciences (NASDAQ: SGHT), an eyecare technology company specializing in innovative interventional technologies, has announced its participation in the Stifel 2025 Virtual Ophthalmology Forum. The company's management will deliver a presentation on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Investors and interested parties can access both the live and archived versions of the fireside chat through the Investors section of Sight Sciences' website at investors.sightsciences.com.

The company focuses on developing and commercializing technologies aimed at transforming care and enhancing patients' lives in the eyecare sector.

Sight Sciences (NASDAQ: SGHT) reported Q1 2025 financial results with total revenue of $17.5 million, marking a 9% decrease year-over-year. The decline was primarily attributed to lower Surgical Glaucoma segment revenue, which fell 6% due to new Medicare LCD restrictions on multiple MIGS procedures during cataract surgery. The company maintained a strong gross margin of 86% and reduced operating expenses by 7% to $29.0 million. Net loss improved to $14.2 million ($0.28 per share) compared to $16.3 million in Q1 2024. Sight Sciences reaffirmed its full-year 2025 revenue guidance of $70.0-75.0 million, representing a 6-12% decline from 2024, and improved its adjusted operating expenses guidance to $101.0-105.0 million. The company launched OMNI Edge with TruSync technology at the ASCRS Annual Meeting, designed to deliver enhanced viscodilation while maintaining safety.

Sight Sciences (Nasdaq: SGHT), an eyecare technology company specializing in innovative interventional technologies, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.

The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results for the quarter ended March 31, 2025. Investors can access the live webcast and replay (available for 90 days) through the company's website at www.sightsciences.com in the Investors page under News & Events section.